Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1996 Jun 15;97(12):2692–2696. doi: 10.1172/JCI118722

Bisphosphonates: mechanisms of action.

G A Rodan 1, H A Fleisch 1
PMCID: PMC507360  PMID: 8675678

Full Text

The Full Text of this article is available as a PDF (122.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. AMPRINO R., ENGSTROM A. Studies on x ray absorption and diffraction of bone tissue. Acta Anat (Basel) 1952;15(1-2):1–22. doi: 10.1159/000140734. [DOI] [PubMed] [Google Scholar]
  2. Adami S., Bhalla A. K., Dorizzi R., Montesanti F., Rosini S., Salvagno G., Lo Cascio V. The acute-phase response after bisphosphonate administration. Calcif Tissue Int. 1987 Dec;41(6):326–331. doi: 10.1007/BF02556671. [DOI] [PubMed] [Google Scholar]
  3. Azuma Y., Sato H., Oue Y., Okabe K., Ohta T., Tsuchimoto M., Kiyoki M. Alendronate distributed on bone surfaces inhibits osteoclastic bone resorption in vitro and in experimental hypercalcemia models. Bone. 1995 Feb;16(2):235–245. doi: 10.1016/8756-3282(94)00035-x. [DOI] [PubMed] [Google Scholar]
  4. Balena R., Toolan B. C., Shea M., Markatos A., Myers E. R., Lee S. C., Opas E. E., Seedor J. G., Klein H., Frankenfield D. The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates. J Clin Invest. 1993 Dec;92(6):2577–2586. doi: 10.1172/JCI116872. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Boonekamp P. M., van der Wee-Pals L. J., van Wijk-van Lennep M. M., Thesing C. W., Bijvoet O. L. Two modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix. Bone Miner. 1986 Feb;1(1):27–39. [PubMed] [Google Scholar]
  6. Boulenc X., Marti E., Joyeux H., Roques C., Berger Y., Fabre G. Importance of the paracellular pathway for the transport of a new bisphosphonate using the human CACO-2 monolayers model. Biochem Pharmacol. 1993 Nov 2;46(9):1591–1600. doi: 10.1016/0006-2952(93)90328-t. [DOI] [PubMed] [Google Scholar]
  7. Boyce B. F., Yoneda T., Lowe C., Soriano P., Mundy G. R. Requirement of pp60c-src expression for osteoclasts to form ruffled borders and resorb bone in mice. J Clin Invest. 1992 Oct;90(4):1622–1627. doi: 10.1172/JCI116032. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Boyce R. W., Paddock C. L., Gleason J. R., Sletsema W. K., Eriksen E. F. The effects of risedronate on canine cancellous bone remodeling: three-dimensional kinetic reconstruction of the remodeling site. J Bone Miner Res. 1995 Feb;10(2):211–221. doi: 10.1002/jbmr.5650100207. [DOI] [PubMed] [Google Scholar]
  9. Cecchini M. G., Felix R., Fleisch H., Cooper P. H. Effect of bisphosphonates on proliferation and viability of mouse bone marrow-derived macrophages. J Bone Miner Res. 1987 Apr;2(2):135–142. doi: 10.1002/jbmr.5650020209. [DOI] [PubMed] [Google Scholar]
  10. Ciosek C. P., Jr, Magnin D. R., Harrity T. W., Logan J. V., Dickson J. K., Jr, Gordon E. M., Hamilton K. A., Jolibois K. G., Kunselman L. K., Lawrence R. M. Lipophilic 1,1-bisphosphonates are potent squalene synthase inhibitors and orally active cholesterol lowering agents in vivo. J Biol Chem. 1993 Nov 25;268(33):24832–24837. [PubMed] [Google Scholar]
  11. Cooper J. A., Howell B. The when and how of Src regulation. Cell. 1993 Jun 18;73(6):1051–1054. doi: 10.1016/0092-8674(93)90634-3. [DOI] [PubMed] [Google Scholar]
  12. Endo N., Rutledge S. J., Opas E. E., Vogel R., Rodan G. A., Schmidt A. Human protein tyrosine phosphatase-sigma: alternative splicing and inhibition by bisphosphonates. J Bone Miner Res. 1996 Apr;11(4):535–543. doi: 10.1002/jbmr.5650110415. [DOI] [PubMed] [Google Scholar]
  13. Evans C. E., Braidman I. P. Effects of two novel bisphosphonates on bone cells in vitro. Bone Miner. 1994 Aug;26(2):95–107. doi: 10.1016/s0169-6009(08)80055-4. [DOI] [PubMed] [Google Scholar]
  14. Fast D. K., Felix R., Dowse C., Neuman W. F., Fleisch H. The effects of diphosphonates on the growth and glycolysis of connective-tissue cells in culture. Biochem J. 1978 Apr 15;172(1):97–107. doi: 10.1042/bj1720097. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Felix R., Graham R., Russell G., Fleisch H. The effect of several diphosphonates on acid phosphohydrolases and other lysosomal enzymes. Biochim Biophys Acta. 1976 Apr 8;429(2):429–438. doi: 10.1016/0005-2744(76)90291-6. [DOI] [PubMed] [Google Scholar]
  16. Felix R., Guenther H. L., Fleisch H. The subcellular distribution of [14C]dichloromethylenebisphosphonate and [14C]1-hydroxyethylidene-1,1-bisphosphonate in cultured calvaria cells. Calcif Tissue Int. 1984 Jan;36(1):108–113. doi: 10.1007/BF02405302. [DOI] [PubMed] [Google Scholar]
  17. Fleisch H., Russell R. G., Francis M. D. Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo. Science. 1969 Sep 19;165(3899):1262–1264. doi: 10.1126/science.165.3899.1262. [DOI] [PubMed] [Google Scholar]
  18. Francis M. D., Russell R. G., Fleisch H. Diphosphonates inhibit formation of calcium phosphate crystals in vitro and pathological calcification in vivo. Science. 1969 Sep 19;165(3899):1264–1266. doi: 10.1126/science.165.3899.1264. [DOI] [PubMed] [Google Scholar]
  19. Gasser A. B., Morgan D. B., Fleisch H. A., Richelle L. J. The influence of two diphosphonates on calcium metabolism in the rat. Clin Sci. 1972 Jul;43(1):31–45. doi: 10.1042/cs0430031. [DOI] [PubMed] [Google Scholar]
  20. Giannini S., D'Angelo A., Malvasi L., Castrignano R., Pati T., Tronca R., Liberto L., Nobile M., Crepaldi G. Effects of one-year cyclical treatment with clodronate on postmenopausal bone loss. Bone. 1993 Mar-Apr;14(2):137–141. doi: 10.1016/8756-3282(93)90240-b. [DOI] [PubMed] [Google Scholar]
  21. Guenther H. L., Guenther H. E., Fleisch H. The influence of 1-hydroxyethane-1,1-diphosphonate and dichloromethanediphosphonate on lysine hydroxylation and cross-link formation in rat bone, cartilage and skin collagen. Biochem J. 1981 Apr 15;196(1):303–310. doi: 10.1042/bj1960303. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Harris S. T., Watts N. B., Jackson R. D., Genant H. K., Wasnich R. D., Ross P., Miller P. D., Licata A. A., Chesnut C. H., 3rd Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy. Am J Med. 1993 Dec;95(6):557–567. doi: 10.1016/0002-9343(93)90350-x. [DOI] [PubMed] [Google Scholar]
  23. Hughes D. E., MacDonald B. R., Russell R. G., Gowen M. Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow. J Clin Invest. 1989 Jun;83(6):1930–1935. doi: 10.1172/JCI114100. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Hughes D. E., Wright K. R., Uy H. L., Sasaki A., Yoneda T., Roodman G. D., Mundy G. R., Boyce B. F. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res. 1995 Oct;10(10):1478–1487. doi: 10.1002/jbmr.5650101008. [DOI] [PubMed] [Google Scholar]
  25. Jung A., Bisaz S., Fleisch H. The binding of pyrophosphate and two diphosphonates by hydroxyapatite crystals. Calcif Tissue Res. 1973 Mar 30;11(4):269–280. doi: 10.1007/BF02547227. [DOI] [PubMed] [Google Scholar]
  26. Kasting G. B., Francis M. D. Retention of etidronate in human, dog, and rat. J Bone Miner Res. 1992 May;7(5):513–522. doi: 10.1002/jbmr.5650070507. [DOI] [PubMed] [Google Scholar]
  27. Liberman U. A., Weiss S. R., Bröll J., Minne H. W., Quan H., Bell N. H., Rodriguez-Portales J., Downs R. W., Jr, Dequeker J., Favus M. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med. 1995 Nov 30;333(22):1437–1443. doi: 10.1056/NEJM199511303332201. [DOI] [PubMed] [Google Scholar]
  28. Murakami H., Takahashi N., Sasaki T., Udagawa N., Tanaka S., Nakamura I., Zhang D., Barbier A., Suda T. A possible mechanism of the specific action of bisphosphonates on osteoclasts: tiludronate preferentially affects polarized osteoclasts having ruffled borders. Bone. 1995 Aug;17(2):137–144. doi: 10.1016/s8756-3282(95)00150-6. [DOI] [PubMed] [Google Scholar]
  29. Nishikawa M., Akatsu T., Katayama Y., Yasutomo Y., Kado S., Kugal N., Yamamoto M., Nagata N. Bisphosphonates act on osteoblastic cells and inhibit osteoclast formation in mouse marrow cultures. Bone. 1996 Jan;18(1):9–14. doi: 10.1016/8756-3282(95)00426-2. [DOI] [PubMed] [Google Scholar]
  30. Ott S. M. Clinical effects of bisphosphonates in involutional osteoporosis. J Bone Miner Res. 1993 Dec;8 (Suppl 2):S597–S606. doi: 10.1002/jbmr.5650081329. [DOI] [PubMed] [Google Scholar]
  31. Parfitt A. M., Mundy G. R., Roodman G. D., Hughes D. E., Boyce B. F. A new model for the regulation of bone resorption, with particular reference to the effects of bisphosphonates. J Bone Miner Res. 1996 Feb;11(2):150–159. doi: 10.1002/jbmr.5650110203. [DOI] [PubMed] [Google Scholar]
  32. Plasmans C. M., Jap P. H., Kuijpers W., Slooff T. J. Influence of a diphosphonate on the cellular aspect of young bone tissue. Calcif Tissue Int. 1980;32(3):247–266. doi: 10.1007/BF02408548. [DOI] [PubMed] [Google Scholar]
  33. Reid I. R., Wattie D. J., Evans M. C., Gamble G. D., Stapleton J. P., Cornish J. Continuous therapy with pamidronate, a potent bisphosphonate, in postmenopausal osteoporosis. J Clin Endocrinol Metab. 1994 Dec;79(6):1595–1599. doi: 10.1210/jcem.79.6.7989461. [DOI] [PubMed] [Google Scholar]
  34. Rogers M. J., Watts D. J., Russell R. G., Ji X., Xiong X., Blackburn G. M., Bayless A. V., Ebetino F. H. Inhibitory effects of bisphosphonates on growth of amoebae of the cellular slime mold Dictyostelium discoideum. J Bone Miner Res. 1994 Jul;9(7):1029–1039. doi: 10.1002/jbmr.5650090710. [DOI] [PubMed] [Google Scholar]
  35. Sahni M., Guenther H. L., Fleisch H., Collin P., Martin T. J. Bisphosphonates act on rat bone resorption through the mediation of osteoblasts. J Clin Invest. 1993 May;91(5):2004–2011. doi: 10.1172/JCI116422. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Sato M., Grasser W. Effects of bisphosphonates on isolated rat osteoclasts as examined by reflected light microscopy. J Bone Miner Res. 1990 Jan;5(1):31–40. doi: 10.1002/jbmr.5650050107. [DOI] [PubMed] [Google Scholar]
  37. Sato M., Grasser W., Endo N., Akins R., Simmons H., Thompson D. D., Golub E., Rodan G. A. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest. 1991 Dec;88(6):2095–2105. doi: 10.1172/JCI115539. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Schenk R., Merz W. A., Mühlbauer R., Russell R. G., Fleisch H. Effect of ethane-1-hydroxy-1,1-diphosphonate (EHDP) and dichloromethylene diphosphonate (Cl 2 MDP) on the calcification and resorption of cartilage and bone in the tibial epiphysis and metaphysis of rats. Calcif Tissue Res. 1973 Mar 12;11(3):196–214. doi: 10.1007/BF02547219. [DOI] [PubMed] [Google Scholar]
  39. Schmidt A., Rutledge S. J., Endo N., Opas E. E., Tanaka H., Wesolowski G., Leu C. T., Huang Z., Ramachandaran C., Rodan S. B. Protein-tyrosine phosphatase activity regulates osteoclast formation and function: inhibition by alendronate. Proc Natl Acad Sci U S A. 1996 Apr 2;93(7):3068–3073. doi: 10.1073/pnas.93.7.3068. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Schweitzer D. H., Oostendorp-van de Ruit M., Van der Pluijm G., Löwik C. W., Papapoulos S. E. Interleukin-6 and the acute phase response during treatment of patients with Paget's disease with the nitrogen-containing bisphosphonate dimethylaminohydroxypropylidene bisphosphonate. J Bone Miner Res. 1995 Jun;10(6):956–962. doi: 10.1002/jbmr.5650100617. [DOI] [PubMed] [Google Scholar]
  41. Shinoda H., Adamek G., Felix R., Fleisch H., Schenk R., Hagan P. Structure-activity relationships of various bisphosphonates. Calcif Tissue Int. 1983;35(1):87–99. doi: 10.1007/BF02405012. [DOI] [PubMed] [Google Scholar]
  42. Storm T., Steiniche T., Thamsborg G., Melsen F. Changes in bone histomorphometry after long-term treatment with intermittent, cyclic etidronate for postmenopausal osteoporosis. J Bone Miner Res. 1993 Feb;8(2):199–208. doi: 10.1002/jbmr.5650080211. [DOI] [PubMed] [Google Scholar]
  43. Troehler U., Bonjour J. P., Fleisch H. Renal secretion of diphosphonates in rats. Kidney Int. 1975 Jul;8(1):6–13. doi: 10.1038/ki.1975.70. [DOI] [PubMed] [Google Scholar]
  44. Vitté C., Fleisch H., Guenther H. L. Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast-mediated resorption. Endocrinology. 1996 Jun;137(6):2324–2333. doi: 10.1210/endo.137.6.8641182. [DOI] [PubMed] [Google Scholar]
  45. Watts N. B., Harris S. T., Genant H. K., Wasnich R. D., Miller P. D., Jackson R. D., Licata A. A., Ross P., Woodson G. C., 3rd, Yanover M. J. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med. 1990 Jul 12;323(2):73–79. doi: 10.1056/NEJM199007123230201. [DOI] [PubMed] [Google Scholar]
  46. Zimolo Z., Wesolowski G., Rodan G. A. Acid extrusion is induced by osteoclast attachment to bone. Inhibition by alendronate and calcitonin. J Clin Invest. 1995 Nov;96(5):2277–2283. doi: 10.1172/JCI118283. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES